PMN PROMIS NEUROSCIENCES INC revenue, earnings and financials
For the quarter ended June 30, 2026, PROMIS NEUROSCIENCES INC reported revenue of n/a, net income of −$11.7M and diluted EPS of −$1.28; for the fiscal year ended December 2025 revenue was n/a.
PMN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$40.2M, net income −$39.7M (margin n/a), EPS −$22.61
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$16.8M, net income $2.78M (margin n/a), EPS $2.63
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$14.3M, net income −$13.2M (margin n/a), EPS −$1.07
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$23.4M, net income −$18.1M (margin n/a), EPS −$2.41
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$8.29M, net income −$9.79M (margin n/a), EPS −$1.69
PMN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$11.7M, EPS −$1.28
- Quarter ended Mar 31, 2026: revenue n/a, net income −$8.24M, EPS −$1.26
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$10.7M, EPS −$9.84
- Quarter ended Sep 30, 2025: revenue n/a, net income −$11.6M, EPS −$0.24
- Quarter ended Jun 30, 2025: revenue n/a, net income −$10.1M, EPS −$7.26
- Quarter ended Mar 31, 2025: revenue n/a, net income −$7.35M, EPS −$5.27
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$238K, EPS $2.64
- Quarter ended Sep 30, 2024: revenue n/a, net income $9.28M, EPS $0.31
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.62M, EPS −$0.13
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.64M, EPS −$0.19
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$3.58M, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.36M, EPS −$0.19
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.31M, EPS −$0.27
- Quarter ended Mar 31, 2023: revenue n/a, net income −$4.96M, EPS −$0.58
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.27M, EPS −$0.91
- Quarter ended Sep 30, 2022: revenue n/a, net income −$5.96M, EPS −$0.83
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.75M, EPS −$0.38
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.09M, EPS −$0.29
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.21M, EPS −$0.20
- Quarter ended Jun 30, 2021: revenue n/a, net income −$226K, EPS −$0.06
PMN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$28.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$27.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$10.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$17.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$9.31M, share buybacks n/a
PMN balance sheet
- Jun 30, 2026: cash $53.4M, total assets $56.7M, total liabilities $7.29M, shareholders' equity $49.4M
- Mar 31, 2026: cash $63.8M, total assets $67.4M, total liabilities $6.69M, shareholders' equity $60.7M
- Dec 31, 2025: cash $6.12M, total assets $9.18M, total liabilities $10.4M, shareholders' equity −$1.26M
- Sep 30, 2025: cash $15.4M, total assets $21.5M, total liabilities $12.3M, shareholders' equity $9.19M
- Jun 30, 2025: cash $4.51M, total assets $9.51M, total liabilities $9.89M, shareholders' equity −$383K
- Mar 31, 2025: cash $8.36M, total assets $13.6M, total liabilities $4.17M, shareholders' equity $9.47M
- Dec 31, 2024: cash $13.3M, total assets $18.9M, total liabilities $2.42M, shareholders' equity $16.5M
- Sep 30, 2024: cash $21.5M, total assets $24.5M, total liabilities $17.2M, shareholders' equity $7.27M
Is PMN profitable?
No. PROMIS NEUROSCIENCES INC lost $42.2M over the last four quarters.
What is PMN's EPS?
Diluted earnings per share over the last four quarters were −$12.62; −$1.28 in the latest quarter.